Buprenorphine depot - Indivior

Drug Profile

Buprenorphine depot - Indivior

Alternative Names: Atrigel buprenorphine; Depot buprenorphine; RBP-6000

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Opioid abuse
  • New Molecular Entity No

Highest Development Phases

  • Phase III Opioid abuse

Most Recent Events

  • 16 Aug 2016 Topline efficacy and safety data from a phase III trial in Opioid abuse released by Indivior
  • 01 Aug 2016 Indivior initiates a phase III extension trial for Opioid abuse in USA (SC) (NCT02896296)
  • 01 Jul 2016 Indivior completes a phase III trial in Opioid abuse in USA (NCT02357901)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top